leisure time -WSS

leisure time

author：focus 2025-09-06 10:37:49 Page View：67

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Setback for rare diseases as Taysha Gene Therapies pulls back

AdobeIn2020,asbiotechstockssurgedamidthepandemic,astartupcalledTayshaGeneTherapiesraisedover$300mill

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

MarkJ.Terrill/APAfollow-upstudyofafirst-of-its-kindcancertreatmentmayreflectsystemicbiases,theFoodan

leisure time

comprehensive

explore

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial